$MDT

KIIL HARRY SKIP sold $337K of MDT

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 4,189 shares of Medtronic plc (MDT) at an average of $80.44 ($80.44–$80.45, $0.34M total) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · KIIL HARRY SKIP
Published Jun 9, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MDT
Neutral
medium confidence
Mentioned
$MDT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with any concurrent company-specific catalysts, but this filing alone does not provide new operational or financial guidance.

02

Market read

A primary-source insider sale disclosure for MDT; sentiment impact is likely limited absent other negative news.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, directional inference is weak.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-09; sale executed 2026-06-08

Background

The article is an SEC Form 4 insider transaction disclosure from Medtronic plc, reporting an open-market sale by a cardiovascular business executive.

Company-level read

Ticker impact

$MDTNeutralMedium confidence
Context

Medtronic insider KIIL HARRY SKIP (EVP & President, Cardiovascular) sold 4,189 shares in open-market transactions on 2026-06-08.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other negative company news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not tied to a 10b5-1 plan and is not large enough (relative to MDT) to imply a fundamental change by itself.

Market effects

Minimal—single-company insider sale without accompanying operational/regulatory updates.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a more meaningful near-term caution signal than typical routine selling.

Key entities

  • Medtronic plc

    MDT, the company whose shares were sold by an executive insider.

  • KIIL HARRY SKIP

    EVP & President, Cardiovascular; reported open-market sale of 4,189 shares.

Related articles

$MDTMed

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Medtronic (NYSE: MDT) said it expanded the CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, including ventricular tachycardia and PVCs. Medtronic also reported FDA Breakthrough Device Designation for Sphere-9 and that the U.S. Sphere VT pivotal trial is enrolling patients.

$MDTMed

Etowah Co. couple awarded $88 million in landmark hernia mesh verdict

A federal jury in Massachusetts awarded Alabama couple Larry and Tammy Patterson $88 million in a hernia mesh case against Covidien, a Medtronic subsidiary. The jury found Covidien failed to adequately warn about risks of its Symbotex mesh. Larry received $77 million and Tammy $11 million. The verdict was the first federal bellwether in a multidistrict litigation with over 2,500 pending suits.

$MDTMedAI 8/10

Medtronic Ordered to Pay $88 Million in First Hernia Mesh Test Trial

A federal jury ordered Medtronic to pay $88 million to an Alabama man and his wife in the first hernia mesh test trial. The case alleged Medtronic’s Covidien division failed to warn about risks of its Symbotex implanted mesh used in 2017. Medtronic said it will seek post-trial relief and appeal, while about 10,350 plaintiffs remain in similar litigation.

$MDTMed

Medtronic faces $88 million verdict in hernia mesh trial

A federal jury ordered Medtronic (NYSE:MDT) to pay $88 million to an Alabama couple in the first hernia mesh trial tied to implants made by its Covidien unit. The jury found Covidien failed to adequately warn of risks, and no punitive damages or fraud were awarded. Medtronic said it will seek post-trial motions and appeal.